Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Chlorthalidone

FDA-approved product (tablet, oral), marketed as Chlorthalidone, Hemiclor, Hygroton and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Chlorthalidone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Angina pectoris
  • Cardiovascular disease
  • Chronic kidney disease
  • Congestive heart failure
  • Glomerulonephritis
  • Heart failure
  • Hypertension
  • Nephrotic syndrome
  • Preeclampsia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonamides, plain
FDA pharmacologic class
Thiazide-like Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli21.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae14.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis68.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Chlorthalidone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Chlorthalidone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Analyzing How Genetics May Affect Response to High Blood Pressure Medications

    NCT00563901 · start 2000-09

    Registered record
    Registry ID
    NCT00563901
    Conditions
    Hypertension; Coronary Disease; Cerebrovascular Accident
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2000-09
    Completion
    2004-05
    Enrolment
    37,939

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Coronary Disease; Cerebrovascular Accident
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

    NCT00000542 · start 1993-08

    Registered record
    Registry ID
    NCT00000542
    Conditions
    Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Heart Diseases; Hypercholesterolemia; Hypertension; Myocardial Infarction; Myocardial Ischemia; Heart Failure
    Interventions
    Inhibitors, ACE; amlodipine; lisinopril; doxazosin; chlorthalidone; pravastatin; diet, fat-restricted
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1993-08
    Completion
    2002-03
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Heart Diseases +5 more
    InterventionInhibitors, ACE; amlodipine; lisinopril; doxazosin +3 more
    PhasePhase 3
    Registry statusCompleted

  • Hypertension Screening and Treatment Program

    NCT00007592 · start 1989-06

    Registered record
    Registry ID
    NCT00007592
    Conditions
    Hypertension
    Interventions
    Chlorthalidone; Furosemide
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    1989-06
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionChlorthalidone; Furosemide
    PhaseNot recorded
    Registry statusCompleted

  • Trial of Antihypertensive Intervention Management

    NCT00000513 · start 1984-04

    Registered record
    Registry ID
    NCT00000513
    Conditions
    Cardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases
    Interventions
    diet, reducing; diet, sodium-restricted; chlorthalidone; atenolol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1984-04
    Completion
    1994-11
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases
    Interventiondiet, reducing; diet, sodium-restricted; chlorthalidone; atenolol
    PhasePhase 3
    Registry statusCompleted

  • Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)

    NCT00000499 · start 1980-09

    Registered record
    Registry ID
    NCT00000499
    Conditions
    Cardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases
    Interventions
    chlorthalidone; reserpine; hydralazine; metoprolol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1980-09
    Completion
    1983-05
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases
    Interventionchlorthalidone; reserpine; hydralazine; metoprolol
    PhasePhase 2
    Registry statusCompleted